Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368989 · ClinicalTrials.gov registry record
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
A clinical trial, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- 21
- Enrollment target
NCT03368989: Completed study, sponsored by The University of Texas Health Science Center, Houston.
NCT03368989 is a clinical trial that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03368989 has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
Primary Outcome
number of lesions specified before and after the treatment with a bone scan
Interventions
- DRUG Radium-223 dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-02-11 |
| Est. Completion | 2017-02-07 |
What the finished NCT03368989 record still lists
NCT03368989 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 dichloride is the first listed.
NCT03368989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03368989 about?
NCT03368989 is a clinical study titled "The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.". To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
What is the current status of trial NCT03368989?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2014-02-11. Estimated completion is 2017-02-07.
What interventions are being tested in trial NCT03368989?
The interventions under investigation include: Radium-223 dichloride (DRUG).
Who is sponsoring clinical trial NCT03368989?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI